AGENDA
CONFERENCE HIGHLIGHTS
The 2019 340B Coalition Winter Conference being held January 30-February 1 in San Diego, CA is just around the corner. Whether you are a health care provider, contract pharmacy, pharmaceutical manufacturer, 340B-oriented business, or government agency, attending the conference is the best way to be informed about 340B. In addition to attending high-quality, cutting-edge sessions on the topics that matter the most to you, there will be ample opportunities to network with your 340B peers and leaders.
Conference sessions will feature the following topics and opportunities:
- The latest developments from Washington, DC on key legislative and regulatory matters impacting the 340B community
- Update from Apexus on key initiatives
- How to prepare for a HRSA audit and take corrective action if needed
- Recent trends in manufacturer inquiries and tips and suggestions for covered entity responses
- An update on issues related to the Medicare Part B payment reduction for 340B drugs
- Medicaid billing and reimbursement requirements
- Strategies for managing inventory in a compliant and efficient manner
- Contract pharmacy compliance and management
- How covered entities use their 340B savings to improve patient access and care
- Breakout sessions for different stakeholder groups to discuss 340B hot topics
- Small group discussions on issues that are important to rural providers and large health care systems
- Opportunities to network with your peers and other attendees
- Opportunity for manufacturers to discuss issues with experts on the 340B program
The conference will also offer the following three pre-conference workshops:
- The essentials of the 340B program for beginners and attendees seeking a 340B refresher course
- An update on recent trends in HRSA audit findings and information from covered entities on how they monitor their 340B programs and strengthen program compliance
- Career development workshop focused on giving you the skills to advance in your career
View the
Agenda-at-a-Glance.